Advances in drug therapy of metastatic castration-resistant prostate cancer
10.12483/j.issn.1009-8291.2026.05.015
- VernacularTitle:转移性去势抵抗性前列腺癌药物治疗进展
- Author:
Danlei MA
1
;
Wei NING
1
Author Information
1. Department of Urology, Urologic Surgery Center, Second Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing 400037, China
- Publication Type:Journal Article
- Keywords:
prostate cancer;
metastatic castration-resistant prostate cancer;
immune checkpoint inhibitors;
antibodydrug conjugates
- From:
Journal of Modern Urology
2026;31(5):481-488
- CountryChina
- Language:Chinese
-
Abstract:
Metastatic castration-resistant prostate cancer (mCRPC) implies highly heterogeneous molecular tumor behavior, rapid disease progression and poorer prognosis, seriously threatening the lives of patients.Therefore, early identification and treatment are significant.Among the current clinical treatment regimens for mCRPC, abiraterone acetate, enzalutamide and docetaxel have demonstrated improvement in overall survival (OS).Furthermore, patients carrying homologous recombination repair mutation (HRRm) are sensitive to poly ADP-ribose polymerase inhibitors (PARPi).For patients with positive prostate specific membrane antigen (PSMA), Lutetium-177 (177Lu)-PSMA-617 radiation ligand therapy is a new and effective treatment method.Radium-223 has also been used as the first-line treatment for patients with bone pain symptoms.However, due to the rapid updates in the field of mCRPC drug therapy, clinicians find it difficult to keep up with the latest developments in this area.Emerging drugs have great potential, such as immune checkpoint inhibitors (ICIs) and antibody-drug conjugates (ADCs), but more evidence is needed, and molecular markers helping predict the efficacy of these drugs should be explored.This article reviews the advances in the drug therapy of mCRPC, with the aim of providing reference for clinical practice.
